Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2025-06-12 Director's Dealing
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - RW 3 pages 7.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of securities held before and after the change, and the nature of the change (cancellation of warrants). This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades or director dealings. It is not a financial report, earnings release, or management announcement. Therefore, the appropriate classification is Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2025-06-12 English
Notice of Change of Interests of Substantial Holder - M Azzi 2 pages 240.0KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and holdings of a substantial shareholder, Mr. Mark Azzi, in Nyrada Inc. It includes specific numbers of shares/CDIs held before and after the change, and references relevant sections of the Corporations Act 2001 (Cth). The document is a formal notification of a change in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification'. The document length is under 5,000 characters and contains detailed shareholding data, confirming it is not a mere announcement of a report but a substantive notification. Therefore, the correct classification is 'MRQ' (Major Shareholding Notification).
2025-06-11 English
Notice of Change of Interests of Substantial Holder - M Azzi 2 pages 226.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Notice of Change of Interests of a Substantial Securityholder, detailing the change in shareholding percentage and number of shares held by Mr. Mark Azzi in Nyrada Inc. It includes specific voting power percentages and references to relevant sections of the Corporations Act 2001 (Cth). The document is a formal announcement of a change in significant share ownership levels, which fits the definition of a Major Shareholding Notification. The document length is under 5,000 characters and contains detailed shareholding information, not a report or announcement of a report publication. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2025-06-04 English
Phase I Clinical Trial Protocol Amendment 4 pages 282.2KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about an amendment to a Phase I clinical trial protocol for a drug candidate, including trial design, endpoints, and regulatory approval from a Human Research Ethics Committee. It provides extensive information about the clinical trial protocol, trial cohorts, and preclinical study results. There is no financial data, earnings information, or regulatory filing typical of financial reports. The document is not a report of financial results, management discussion, or governance. It is a corporate announcement related to clinical trial progress and protocol changes, which does not fit into financial or regulatory filing categories such as Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or certification. The closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories. The document is about a clinical trial protocol amendment and trial updates, which is a regulatory announcement type but not a financial report. Confidence is high given the clear nature of the content and absence of financial data.
2025-06-03 English
Notice of Change of Interests of Substantial Holder - M Azzi 2 pages 235.9KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and holdings of a substantial shareholder, Mr. Mark Azzi. It includes specific numbers of shares/CDIs held before and after the change, and references relevant sections of the Corporations Act 2001. The document is a formal notification of a change in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (MRQ). The document length is 4045 characters, which is consistent with a notice rather than a full report. There is no indication of financial results, management discussion, or other report types. Therefore, the correct classification is MRQ with high confidence.
2025-06-02 English
Notice of Change of Interests of Substantial Holder - M Azzi 2 pages 221.9KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and shareholdings of a substantial shareholder, Mr. Mark Azzi. It includes specific numbers of shares/CDIs held before and after the change, and references relevant sections of the Corporations Act 2001 (Cth). There is no financial performance data, earnings information, or management discussion. The document is a notification of a change in significant share ownership levels, which fits the definition of 'Major Shareholding Notification'. The document length is 4001 characters, which is consistent with a detailed notification rather than a full report or announcement of a report publication. Therefore, the appropriate classification is 'MRQ' (Major Shareholding Notification).
2025-05-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.